Stocktoria
Neuphoria Therapeutics Inc. NEUP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1999-12-21
Neuphoria Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $15.6M | — | — |
| R&D expense | $9.0M | $9.4M | $13.1M |
| Operating income | -$1.1M | -$17.9M | -$22.0M |
| Income tax | -$468,366 | -$87,320 | -$139,174 |
| Net income | -$400,000 | -$15.5M | -$21.4M |
| EPS (diluted) | $-0.23 | $-18.62 | $-0.02 |
| Operating cash flow | $77,229 | -$14.7M | -$14.6M |
| Cash & equivalents | $14.2M | $12.6M | $12.1M |
| Total assets | $28.6M | $27.6M | $28.6M |
| Total liabilities | $9.6M | $10.2M | $6.6M |
| Shareholders' equity | $19.0M | $17.5M | $22.0M |
Source: SEC EDGAR filings · CIK 0001191070 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.